Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM53J6B)

Drug Name
PDR001 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Esophageal squamous cell carcinoma 2E60.1 Phase 2 [2]
Neuroendocrine cancer 2B72.1 Phase 2 [3]
Lymphoma 2A80-2A86 Phase 1 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Cross-matching ID
TTD Drug ID
DM53J6B

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Antagonist [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Programmed cell death protein 1 (PD-1) DTT PDCD1 5.635 4.661 4.706 5.15
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Skin
The Studied Disease Melanoma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02967692) A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03785496) Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)